Navigation Links
Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project
Date:1/5/2009

of repetitive strain injury (RSI) for staff. We also had experienced drug errors (when you are very busy it is easy to pick the wrong vial or bag) but with CytoCare(TM), correct vial and bag identification and picking is now assured with no errors. The use of CytoCare(TM) has also resulted in efficiency gains for the pharmacy. It has reduced the steps in the preparation process and the overall preparation time. Work-study results show that the technicians' time has been reduced from 80 hours to 12 hours. In addition, only one technician is required to operate CytoCare(TM) whereas two technicians are needed when chemotherapy IVs are manually prepared in a BSC, one to make the product and another one to look. A further benefit is that it takes less time to train a technician to work with CytoCare(TM) than to work in a BSC."

About Imperial College Healthcare NHS Trust, University of London, UK:

Imperial College Healthcare NHS Trust has a very strong history of education and research. It is the UK's first Academic Health Sciences Centre and the largest NHS Trust in the UK with combined annual production of around 27,000 patient-specific chemotherapy IV doses. It is composed of the teaching hospitals Charing-Cross, St, Mary's, Hammersmith, Queen Charlotte's and Chelsea, and Western Eye Hospital.

About RAP Capital Region Pharmacy, Copenhagen University Hospital:

Rigshospitalet Apoteket is the hospital pharmacy for the Capital Region of Denmark. RAP delivers pharmacy services under GMP regulations to 14 hospitals serving 2,300 wards [nurse stations]. The yearly turnover is EUR200 million, and the 460-staff includes 75 pharmacists and 230 technicians. RAP supports three centers for cancer treatment and prepares approximately 80,000 patient-specific chemotherapy IV doses annually.

About General Hospital of Bolzano, Italy:

The 850-bed General Hospital of Bolzano
'/>"/>

SOURCE Health Robotics SRL
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
2. West Penn Allegheny Health System Announces Recruitment of Leading Burn Specialists
3. Cardinal Health Executives to Speak at J.P. Morgan 27th Annual Healthcare Conference
4. Accuray Incorporateds CEO to Speak at 27th Annual JP Morgan Healthcare Conference
5. Health Robotics Announces Partnership in the Peoples Republic of China With The Devon International Group
6. ICU Medical Inc. and Health Robotics Announce Compatibility of CytoCare(TM) Robot and CLAVE(R) Needle-Free Connector to Enable Safer Hazardous Drug Handling
7. NxStage to Present at the JPMorgan Healthcare Conference
8. Cascades Technologies, Inc. and SAIC Team on $19 Million Contract with National Institutes of Health
9. WellCentive Launches New Health Information Exchange Platforms
10. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
11. Kaiser Permanente CEO Calls for Connected Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... 1 safety studies, and plans for Phase 2 studies ... to be presentedCINCINNATI, May 14 Ausio Pharmaceuticals, LLC, ... aging global population, will lead off the Bio(R) Business ... 9:00 AM in Atlanta, Georgia. Ausio has developed AUS-131, ...
... Phase 3 CAPACITY results poster presentation Sunday, May 17, 8:15 ... presentation, Tuesday, May 19, 3:35 p.m. PDT - - ... - BRISBANE, Calif., May 14 InterMune, Inc. (Nasdaq: ... presentation and two poster discussion presentations related to the company,s ...
... with substantially increased capacity, for continued ... announced today robust double digit growth in sales, improved ... quarter ended March 31, 2009. , In a news ... "Our 43% growth in the first half of 2009 ...
Cached Biology Technology:Ausio Pharmaceuticals to Present at Bio(R) 2009 2Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 2Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 3Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 4Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 5Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 2Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 3Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 4
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... MOUNTAIN VIEW, CA January 25, 2011 23andMe,s ... both phenotypic and genetic data from 500 individuals diagnosed ... way towards its goal of building a sarcoma research ... completed its Independent Sarcoma Scientific Advisory Committee with the ...
... lethal form of brain cancer and the disease that ... efforts, even when attacked simultaneously on several fronts. One ... flexibility, discovered researchers at the Salk Institute for Biological ... glioblastoma cells can shift gears and morph into blood ...
... Baltimore, Md. (January 24, 2011) A research effort designed ... a research hatchery could end up helping Chesapeake Bay watermen ... shell crabs perishing before reaching the market. The findings, published ... that the transmission of a crab-specific virus in diseased and ...
Cached Biology News:23andMe sarcoma research community reaches 500 and announces Sarcoma Scientific Advisory Committee 2Conversion of brain tumor cells into blood vessels thwarts treatment efforts 2Conversion of brain tumor cells into blood vessels thwarts treatment efforts 3Blue crab research may help Chesapeake Bay watermen improve soft shell harvest 2
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
...
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
Biology Products: